At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 69 enrolled
Drug / intervention
Ciraparantag +2 moredrug
Likely dose
Rivaroxaban 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Placebo-Controlled, Single-Site, Single-Blind Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.·interventional·Posted Jun 1, 2017·Updated Sep 2, 2025
In Brief
A Phase 2 clinical trial evaluating Ciraparantag, Placebo, and 1 other intervention for Healthy. Completed, enrolled 69 participants across 1 site.
Detailed Summary
This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with rivaroxaban measuring clotting times using Whole Blood Clotting Time (WBCT).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartMay 2017
First PostedJun 2017
Primary CompletionNov 2019
TodayJul 2026
First PostedJun 1, 2017
Enrollment StartMay 8, 2017
Primary CompletionNov 12, 2019
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 9.1 years ago
Interventions
Ciraparantagdrug
Ciraparantag (administered over 10 minutes)
Placebodrug
Saline for injection
Rivaroxabandrug
Rivaroxaban 20 mg given once per day (QD) in the morning